Modality
mAb
MOA
EZH2i
Target
KRASG12C
Pathway
Sphingolipid
IPFPNHOCD
Development Pipeline
Preclinical
~Mar 2010
→ ~Jun 2011
Phase 1
~Sep 2011
→ ~Dec 2012
Phase 2
~Mar 2013
→ ~Jun 2014
Phase 3
~Sep 2014
→ ~Dec 2015
NDA/BLA
~Mar 2016
→ ~Jun 2017
Approved
Sep 2017
→ Jun 2031
ApprovedCurrent
NCT07819705
2,691 pts·OCD
2018-06→2031-03·Terminated
NCT08966780
1,256 pts·OCD
2025-10→2026-06·Active
NCT05512667
2,862 pts·PNH
2021-09→TBD·Recruiting
+1 more trial
9,195 total pts3 indications
CompletedCurrentUpcoming
Catalysts (3)
2026-06-243mo awayPh3 Readout· OCD
2031-03-205.0y awayPh3 Readout· OCD
2031-06-265.2y awayPh3 Readout· IPF
Trial Timeline
Q3Q42018Q2Q3Q42019Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030Q2Q3Q42031Q2Q3Q4
Approved
Active
Approved
Termina…
Approved
Recruit…
Approved
Active
Catalysts
Ph3 Readout
2026-06-24 · 3mo away
OCD
Ph3 Readout
2031-03-20 · 5.0y away
OCD
Ph3 Readout
2031-06-26 · 5.2y away
IPF
RecruitingActiveTerminated|StartCompletionToday
Trials (4)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT07819705 | Approved | OCD | Terminated | 2691 | NT-proBNP |
| NCT08966780 | Approved | OCD | Active | 1256 | CfB |
| NCT05512667 | Approved | PNH | Recruiting | 2862 | 6MWD |
| NCT06408641 | Approved | IPF | Active | 2386 | Safety |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| JNJ-179 | Johnson & Johnson | Approved | KRASG12C | |
| Adagrazumab | Novartis | Phase 2/3 | Cl18.2 | |
| Ribotuximab | Merck & Co | Phase 2 | GPRC5D | |
| BMY-4586 | Bristol-Myers Squibb | Preclinical | KRASG12C | |
| Doxarapivir | Bristol-Myers Squibb | Phase 3 | KRASG12C | |
| NVO-9615 | Novo Nordisk | Phase 2/3 | PRMT5 | |
| AMG-4531 | Amgen | Phase 2/3 | KRASG12C | |
| REG-8074 | Regeneron | Phase 2/3 | KRASG12C | |
| VRT-1891 | Vertex Pharma | Phase 1 | KRASG12C | |
| Pemitapinarof | BeiGene | Approved | KRASG12C |